Does growth efficiency determine the inoculum effect?
生长效率决定接种效果吗?
基本信息
- 批准号:10359939
- 负责人:
- 金额:$ 46.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-17 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdjuvant TherapyAffectAmericanAntibiotic TherapyAntibioticsAttenuatedBacteriaBacterial Antibiotic ResistanceBacterial InfectionsBiochemical PathwayBioinformaticsBiomassCase StudyCell DensityCessation of lifeClinicClinicalComputer SimulationCoupledDataDevelopmentDoseESKAPE pathogensEnvironmentEquilibriumEscherichia coliEvolutionFoodGenerationsGenesGoalsGrowthHospital CostsIn VitroInfectionInterdisciplinary StudyKlebsiella pneumoniaeKnock-outLeadMeasuresMetabolic PathwayMetabolismMinimum Inhibitory Concentration measurementModelingMolecularPathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhasePopulationPopulation DensityPredispositionProtocols documentationPseudomonas aeruginosaPublic HealthResearchResistanceRiskRoleSourceStaphylococcus aureusTestingTreatment ProtocolsWorkantibiotic tolerancebacterial metabolismclinically relevantdensityeffectiveness evaluationexhaustexperienceexperimental studygraduate studentimprovedin vivointerestmathematical modelmetabolic ratemortalitynew therapeutic targetnovelnovel therapeuticspathogensuccessundergraduate student
项目摘要
Project Summary/Abstract
2.8 million Americans are infected with antibiotic resistant bacteria annually. This leads to increased deaths and
hospital costs. Moreover, there are few new antibiotics being developed. There is a dire need to extend the
usefulness of existing antibiotics by understanding how bacteria tolerate antibiotic treatment. One way that
bacteria tolerate antibiotics is the inoculum effect (IE), where the initial density of a bacterial population
determines the concentration of antibiotic required to kill the population: a population of bacteria with a higher
density will require more antibiotics to kill. IE has been observed in nearly all bacteria and antibiotics, and in the
clinical setting. Surprisingly, we currently do not have treatment approaches that reduce IE, which would increase
the ability to treat infections. It has been recently discovered that bacterial metabolic rate can determine the
effectiveness of antibiotics. A higher metabolic rate reduces the amount of antibiotic required to kill a population
of bacteria. This finding is particularly relevant in the context of IE, as bacterial density, metabolism, and growth
are interrelated. Highly dense populations have a short period of growth before they exhaust their food source.
This small window of growth leads to an overall low metabolic rate. Lower density populations have a longer
period of growth before exhausting their food source. This long period of growth leads to an overall high metabolic
rate. Thus, due its overall higher metabolic rate, the population with low density would require less antibiotic to
kill relative to the high density population. This relationship between growth rate and metabolism can be
described as growth efficiency. It is possible that changes in growth efficiency can determine IE, but we have
not yet studied this. This is an important question to address as there is growing interest in using metabolite
adjuvants with antibiotic treatment to increase antibiotic efficacy. However, without knowing how metabolism, or
growth efficiency, affect IE, we risk enhancing the ability of bacteria tolerate antibiotics, which will complicate
infections. The goal of this research is to investigate how growth efficiency determines IE. This will help us
achieve our long term goal of altering bacterial metabolism to make bacteria easier to kill using antibiotics. To
address our goal, we will first examine how growth efficiency determines IE in Pseudomonas aeruginosa and
Staphylococcus aureus with a goal of determining growth conditions that can reduce, or even eliminate, IE. Next,
we will discover what genes and biochemical pathways determine growth efficiency and IE towards developing
a molecular mechanism. Our work may lead to the development of new antibiotics that reduce, or eliminate, IE.
We will use a combination of experiments that measure growth, metabolism and the ability of antibiotics to kill
bacteria. We will couple these experiments with mathematical modeling, computer simulations and
bioinformatics. The proposed work will involve graduate and undergraduate students in interdisciplinary research
with a focus on understanding antibiotic tolerance.
项目总结/文摘
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sub-inhibitory antibiotic treatment selects for enhanced metabolic efficiency
- DOI:10.1128/spectrum.03241-23
- 发表时间:2024-01-16
- 期刊:
- 影响因子:3.7
- 作者:Aduru,Sai Varun;Szenkiel,Karolina;Lopatkin,Allison J.
- 通讯作者:Lopatkin,Allison J.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert P Smith其他文献
Robert P Smith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 46.25万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 46.25万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 46.25万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 46.25万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 46.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 46.25万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 46.25万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 46.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 46.25万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 46.25万 - 项目类别:
Operating Grants